Skip to content
Screener

Intellia Therapeutics NTLA Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$23.0MBeat by $11.0M
EPS-$0.83Beat by $0.16
Revenue estimate$12.0M
EPS estimate-$0.99

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$9.7M
EPS estimate-$0.82

Financials

Q4 2025

Income statement

See full
Revenue$23.0M+78.8%
Operating income-$98.7M+27.7%
Net income-$95.8M+25.7%
EPS (diluted)-$0.82+34.9%

Balance sheet

See full
Cash & equivalents$155.5M-17.8%
Total debt$93.3M-55.6%
Total equity$671.4M-23.0%
Total assets$842.1M-29.3%

Cash flow

See full
Operating cash flow-$69.3M+18.7%
CapEx$126.0K-87.2%
Free cash flow-$69.4M+19.5%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.04B-12.3%
Enterprise value$979.18M-19.0%
P/S15.4×-5.1×

Profitability

See full
Operating margin-651.7%-148pp
Net margin-609.9%-148pp
FCF margin-585%-25.4pp

Returns & leverage

See full
Return on equity-53.5%-0.5pp
Debt / equity0.1×-0.1×
Current ratio5.1×-0.7×

FAQ

When did Intellia Therapeutics report Q4 2025 earnings?
Intellia Therapeutics (NTLA) reported Q4 2025 earnings on February 26, 2026 before market open.
What were Intellia Therapeutics's Q4 2025 revenue and EPS?
Intellia Therapeutics reported revenue of $23.0M and eps of $-0.83 for Q4 2025.
Did Intellia Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $12.0M by $11.0M. EPS beat the consensus estimate of $-0.99 by $0.16.
How did Intellia Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 78.8% from $12.9M a year earlier and eps grew 33.1% from $-1.24.
Where can I find Intellia Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-073456) and the 10-K periodic report (0001193125-26-076550) directly on SEC EDGAR. The filing index links above go to sec.gov.